Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral itraconazole for severe epistaxis in hereditary hemorrhagic telangiectasia
2017-003272-31Phase 2Active
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of itraconazole in hereditary hemorrhagic telangiectasia (HHT), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Epistaxis severity score. Started Jan 2018; status: active.
02
Drugs
itraconazole
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2017-003272-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003272-31.